NCT01121042View on ClinicalTrials.gov

Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Schizoaffective and Schizophreniform DisordersSchizophrenia
Interventions
DRUG

Ondansetron

8mg per day oral capsule

DRUG

Placebo

daily oral capsule matched to active study medication. Made form 100% lactose powder

Trial Locations (1)

3004

Monash Alfred Psychiatry Research Centre (MAPrc), Melbourne

Sponsors

Lead Sponsor

Bayside Health
All Listed Sponsors
lead

Bayside Health

OTHER_GOV